{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:31:31Z","timestamp":1785429091581,"version":"3.56.0"},"update-to":[{"DOI":"10.1016\/j.ijregi.2025.100665","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000}}],"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJID Regions"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijregi.2025.100665","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T02:43:27Z","timestamp":1746758607000},"page":"100665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["RETRACTED: Anti-tuberculosis drug\u2013induced hepatotoxicity and associated risk factors among patients with pulmonary tuberculosis at a tertiary care hospital in Thailand"],"prefix":"10.1016","volume":"15","author":[{"given":"Sarita","family":"Mukura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9377-8115","authenticated-orcid":false,"given":"Parinya","family":"Ruenwilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijregi.2025.100665_bib0001","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0033354919884302","article-title":"Noncountable tuberculosis case reporting, national tuberculosis surveillance system, United States, 2010\u20132014","volume":"135","author":"Pratt","year":"2020","journal-title":"Public Health Rep"},{"key":"10.1016\/j.ijregi.2025.100665_bib0002","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12879-018-3347-7","article-title":"A case report of mucocutaneous tuberculosis after orthotopic liver transplantation: a challenging diagnosis","volume":"18","author":"Riccardi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijregi.2025.100665_bib0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4046\/trd.2015.78.3.161","article-title":"Treatment of drug susceptible pulmonary tuberculosis","volume":"78","author":"Shin","year":"2015","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.ijregi.2025.100665_bib0004","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00228-016-2083-4","article-title":"Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring","volume":"72","author":"Verbeeck","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijregi.2025.100665_bib0005","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.12688\/f1000research.125815.1","article-title":"Characteristics and contributing factors of adverse drug reactions: an analytical study of patients with tuberculosis receiving treatment under the National TB Program of India","volume":"11","author":"Shah","year":"2022","journal-title":"F1000Res"},{"key":"10.1016\/j.ijregi.2025.100665_bib0006","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijregi.2025.100665_bib0007","first-page":"688","article-title":"Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia","volume":"49","author":"Marzuki","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1016\/j.ijregi.2025.100665_bib0008","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijregi.2025.100665_bib0009","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/infdis\/jiae025","article-title":"Prediction models for adverse drug reactions during tuberculosis treatment in Brazil","volume":"229","author":"Ridolfi","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijregi.2025.100665_bib0010","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.ijregi.2025.100665_bib0011","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/cid\/ciab598","article-title":"A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes","volume":"74","author":"Peetluk","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijregi.2025.100665_bib0012","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijid.2020.11.140","article-title":"Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: the example of RePORT Brazil","volume":"103","author":"Arriaga","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijregi.2025.100665_bib0013","first-page":"384","article-title":"Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity","volume":"26","author":"Abbasi","year":"2014","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.ijregi.2025.100665_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HMER.S290542","article-title":"Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia","volume":"13","author":"Molla","year":"2021","journal-title":"Hepat Med"},{"key":"10.1016\/j.ijregi.2025.100665_bib0015","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/molecules25133011","article-title":"The war against tuberculosis: a review of natural compounds and their derivatives","volume":"25","author":"Maiolini","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ijregi.2025.100665_bib0016","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijregi.2025.100665_bib0017","first-page":"ciae583","article-title":"NAT2 slow acetylator phenotype as a significant risk factor for hepatotoxicity caused by antituberculosis drugs: results from a multiethnic nested case-control study","author":"Cheli","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijregi.2025.100665_bib0018","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000062","article-title":"PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2","volume":"24","author":"McDonagh","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ijregi.2025.100665_bib0019","series-title":"Clinical and Research Information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.ijregi.2025.100665_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12920-021-00926-x","article-title":"Association of NAT2 genetic polymorphism with the efficacy of Neurotropin\u00ae for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study","volume":"14","author":"Nakai","year":"2021","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.ijregi.2025.100665_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044687","article-title":"Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults","volume":"11","author":"Peetluk","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijregi.2025.100665_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186200","article-title":"Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients","volume":"12","author":"Chan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijregi.2025.100665_bib0023","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijtb.2019.11.005","article-title":"Adverse drug reactions in tuberculosis and management","volume":"66","author":"Prasad","year":"2019","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijregi.2025.100665_bib0024","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.apsb.2016.07.014","article-title":"Isoniazid metabolism and hepatotoxicity","volume":"6","author":"Wang","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ijregi.2025.100665_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.ijregi.2025.100665_bib0026","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13104-019-4872-1","article-title":"Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital, Ethiopia","volume":"13","author":"Zeleke","year":"2020","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.ijregi.2025.100665_bib0027","first-page":"1374","article-title":"Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review","volume":"14","author":"Kunst","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijregi.2025.100665_bib0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4292\/wjgpt.v12.i3.40","article-title":"Overview of drug induced liver injury in Brazil: what is the role of public health policy on the evidence?","volume":"12","author":"Becker","year":"2021","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.ijregi.2025.100665_bib0029","first-page":"519","article-title":"Tuberculosis burden in Ethiopia from 1990 to 2016: evidence from the global burden of diseases 2016 study","volume":"28","author":"Deribew","year":"2018","journal-title":"Ethiop J Health Sci"},{"key":"10.1016\/j.ijregi.2025.100665_bib0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12072-021-10144-3","article-title":"Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines","volume":"15","author":"Devarbhavi","year":"2021","journal-title":"Hepatol Int"}],"updated-by":[{"DOI":"10.1016\/j.ijregi.2025.100734","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000}},{"DOI":"10.1016\/j.ijregi.2025.100665","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000}}],"container-title":["IJID Regions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772707625001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772707625001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:13:09Z","timestamp":1762647189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772707625001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"alternative-id":["S2772707625001006"],"URL":"https:\/\/doi.org\/10.1016\/j.ijregi.2025.100665","relation":{},"ISSN":["2772-7076"],"issn-type":[{"value":"2772-7076","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: Anti-tuberculosis drug\u2013induced hepatotoxicity and associated risk factors among patients with pulmonary tuberculosis at a tertiary care hospital in Thailand","name":"articletitle","label":"Article Title"},{"value":"IJID Regions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijregi.2025.100665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"100665"}}